Compare DexCom, Inc. (DXCM) vs Flagstar Bank NA (FLG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Flagstar Bank NA — how do they compare? DexCom, Inc. trades at $83.72 (market cap $31.86B), while Flagstar Bank NA trades at $11.25 (market cap $4.71B). The key difference: DexCom, Inc. is far larger — about 6.8× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.35% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Flagstar Bank NA for 21 Days on average.
| DXCM | FLG | |
|---|---|---|
Market Cap | $31.86B | $4.71B |
Volume | 3,607,070 | 7,410,589 |
Sector | Health | Financials |
52-Week High | $92.34 | $15.36 |
52-Week Low | $54.84 | $10.72 |
Typical Hold Time | 62 Days | 21 Days |
Enterprise Value | $31.32B | $15.25B |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
FLG trades at $11.21, down 0.8% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 378.33 but attractive P/B of 0.62, while transitioning from a $177M loss in 2025 to profitability in 2026. Recent news highlights strategic partnerships and a $250M share repurchase program, though Q2 2026 earnings missed expectations.
Analyst consensus remains bullish with a $17.07 price target (60% buy ratings), offering significant upside potential. Key risks include volatile cash flows and competitive banking pressures. The current discount to book value and institutional support suggest long-term value if profitability trends continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →
